Search

Mindful Innovation

Mastering Challenges. Compassion for Patients. Transforming Medicine.

At Marinus Pharmaceuticals, our passionate team of experts is constantly innovating with the aim to drastically improve lives affected by rare epilepsies and neuropsychiatric disorders.

Icon Commitment

Commitment

Improving lives of patients suffering from seizures and neuropsychiatric disorders 

Learn more

Icon Innovation

Innovation

Maximizing the reach of ganaxolone to make a difference in patient lives  

Learn more

Icon Community

Community

We partner with leading epilepsy and neuropsychiatric patient advocacy groups 

Learn more

We are laser focused on treating patients with severe, rare forms of epilepsy, implementing a clinical trial strategy that is guided by our strong scientific rationale, and unlocking the potential of ganaxolone across a range of CNS disorders. 

— Scott Braunstein, M.D., CEO, Marinus Pharmaceuticals

  • Ganaxolone

    Dedicated to the development of ganaxolone

    We are dedicated to maximizing the value of ganaxolone as a first-in-class innovative neuropsychiatric therapy with a portfolio of diversified indications.

    Learn more about ganaxolone

  • Pipeline

    Discover the science behind ganaxolone

    Ganaxolone, through its validated GABAA mechanism, has opportunities in orphan indications and in chronic and acute care settings.

    View our pipeline

  • Focus Areas

    Focused on rare seizure and neuropsychiatric disorders

    We are developing breakthrough therapies in status epilepticus, tuberous sclerosis complex, PCDH19-related epilepsy, and CDKL5 deficiency disorder.

    Learn more about our focus areas

  • Trials

    Our goal is developing safe and effective treatments

    We are conducting high quality research in-house, with our scientific advisory board and external consultants to ensure patients are receiving innovative and safe treatment options.

    Learn more about our active trials on ClinicalTrials.gov

Providing a range of clinical trials to develop innovative treatments for patients

Physician Child Epilepsy 1

Status Epilepticus

Striving to maintain seizure control

Developing therapies with the potential to provide rapid cessation of status epilepticus and prevent escalation of treatment

Learn more

CDLK5 deficiency disorder

Aspiring to give children significantly less seizures and better quality of life

Ganaxolone offers the potential to safely decrease seizure frequency in children with refractory epilepsy

Learn more

Advocacy

Fostering a community for those impacted by rare diseases

Collaborating with key groups to support patients and their families, working to lessen the burden of rare diseases and disorders

Learn more

Svg Graphic Neurology 1

Follow Us on Twitter

Here is my summary from the 2020 #CDKL5 Forum hosted by the Loulou Foundation. Some key messages:
- CDD is not really a "neurodevelopmental disorder"
- gene therapies (in plural) are coming
- and in 2020 we had THREE positive clinical trials in CDD
👇👇

http://www.draccon.com/dracaena-report/cdkl5forum2020

There are limited disease-specific treatments approved for #TSC patients. Our Phase 2 open-label trial is evaluating ganaxolone in patients with seizures associated with the disorder.

For more on eligibility criteria for the study, visit: http://www.marinuspharma.com/patients/tuberous-sclerosis-complex-tsc

As we kick off our second Virtual TSC and LAM Conference co-hosted with @LAMFoundation we would like to thank all of the sponsors who made this series possible!

Thank you @UCBUSA, @GreenwichBio, Upsher-Smith, @MNK, @massmutual, @NobelpharmaUS, @Novartis and @MarinusPharma!

Home Join The Marinus Team

Want to make an impact?

We are always looking for dedicated and passionate professionals who want to make a positive difference in the lives of those affected by rare epilepsies and neuropsychiatric disorders.

Join us